(Q37999956)

26 August 2017

title

Leishmaniasis: vaccine candidates and perspectives (English)

1 reference

26 August 2017

2

Shyam Sundar

1 reference

26 August 2017

Bhawana Singh

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

30

1 reference

26 August 2017

issue

26

1 reference

26 August 2017

page(s)

3834-3842

1 reference

Visceral leishmaniasis: elimination with existing interventions

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmaniasis: current status of vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

First generation leishmaniasis vaccines: a review of field efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

A member of the ClpB family of stress proteins is expressed during heat shock in Leishmania spp.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

High constitutive levels of heat-shock proteins in human-pathogenic parasites of the genus Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Inhibition of HSP90 in Trypanosoma cruzi induces a stress response but no stage differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The heat shock protein 90 of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Identification and characterisation of a Leishmania donovani antigen belonging to the 70-kDa heat-shock protein family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The heat shock protein HSP70 and heat shock cognate protein HSC70 contribute to antimony tolerance in the protozoan parasite leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Major surface protease of trypanosomatids: one size fits all?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Cysteine protease inhibitors as chemotherapy: lessons from a parasite target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

NO donors inhibit Leishmania infantum cysteine proteinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Cysteine protease as a target for nitric oxide in parasitic organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania histone H1 overexpression delays parasite cell-cycle progression, parasite differentiation and reduces Leishmania infectivity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Translocation of histone proteins across lipid bilayers and Mycoplasma membranes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Genomic organization and gene expression in a chromosomal region of Leishmania major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The DEAD-box protein family of RNA helicases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

RNA helicases: modulators of RNA structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania infantum LeIF protein is an ATP-dependent RNA helicase and an eIF4A-like factor that inhibits translation in yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Surface glycoprotein PSA (GP46) expression during short- and long-term culture of Leishmania chagasi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Cloning, sequencing, and expression of the PSA genes from Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leucine rich repeats are the main epitopes in Leishmania infantum PSA during canine and human visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

TheLeishmaniapromastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity toL. major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Molecular determinants of Leishmania virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Characterizing cellular immune response to kinetoplastid membrane protein-11 (KMP-11) during Leishmania (Viannia) panamensis infection using dendritic cells (DCs) as antigen presenting cells (APCs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Reduced expression of lipophosphoglycan (LPG) and kinetoplastid membrane protein (KMP)-11 in Leishmania donovani promastigotes in axenic culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Metabolism and functions of trypanothione in the Kinetoplastida

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Evidence that trypanothione reductase is an essential enzyme in Leishmania by targeted replacement of the tryA gene locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The stage-regulated HASPB and SHERP proteins are essential for differentiation of the protozoan parasite Leishmania major in its sand fly vector, Phlebotomus papatasi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania major LACK antigen is required for efficient vertebrate parasitization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156 to 173 is not required for early Th2 development in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Compartmentation of carbohydrate metabolism in trypanosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Structure-based drug design: progress, results and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Cloning of Leishmania nucleoside transporter genes by rescue of a transport-deficient mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Cloning of a novel inosine-guanosine transporter gene from Leishmania donovani by functional rescue of a transport-deficient mutant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

LmxMPK9, a mitogen-activated protein kinase homologue affects flagellar length in Leishmania mexicana.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Drug targets in Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Topoisomerases of kinetoplastid parasites: why so fascinating?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania mitochondrial tRNA importers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Mitochondria and trypanosomatids: targets and drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Examination of variables in the vaccination of mice against cutaneous leishmaniasis using living avirulent cloned lines and killed promastigotes of Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Expression cloning of a protective Leishmania antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

BCG Expressing LCR1 of Leishmania chagasi Induces Protective Immunity in Susceptible Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.068

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.03.068

1 reference

release_yaqpdznowze7hbpbfasv2cgj3m

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yaqpdznowze7hbpbfasv2cgj3m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference